-+ 0.00%
-+ 0.00%
-+ 0.00%

Viridian Therapeutics Expects Cash, Anticipated Revenue to Fund Business Plans Through Profitability

PUBT·11/04/2026 13:10:09
Listen to the news
Viridian Therapeutics Expects Cash, Anticipated Revenue to Fund Business Plans Through Profitability
  • Viridian Therapeutics expects current cash and anticipated revenues to fund its current business plans through profitability.
  • Cash, cash equivalents and marketable securities totaled $955 million.
  • Lumvoa generated $24.7 million in third-quarter 2026 net product revenue, with more than 100 patients on therapy as of September 30.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.